Repligen has completed its acquisition of BioLife Solutions, adding a cell and gene therapy tools business that it says strengthens its position in the cell therapy market.
Under the deal, BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock for each BioLife share, plus cash for fractional shares.
Repligen said BioLife brings a biopreservation media portfolio led by CryoStor that supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. The company also highlighted BioLife’s consumables business as a high-margin, recurring-revenue asset.
The transaction expands Repligen’s reach beyond its core bioprocessing portfolio into a market it described as rapidly growing. Repligen said the combined business will have broader global reach, including Asia Pacific, and will benefit from BioLife’s customer relationships.
Repligen said it expects to provide more detail on the acquisition’s impact on its 2026 financial outlook during its third-quarter 2026 earnings call. Following these announcements, the company's shares moved 4.29%, and are now trading at a price of $189.50. For more information, read the company's full 8-K submission here.
